Sleep Medicine Devices Earn 2026 Red Dot Product Design Awards
Innovations in home sleep testing, CPAP therapy, and EEG were recognized for their design and usability in the international competition.
Innovations in home sleep testing, CPAP therapy, and EEG were recognized for their design and usability in the international competition.
A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.
ABM was acquired by Cadence Health Capital last month. A new leadership team at the neurology-forward sleep company plans to streamline operations and expand the clinical reach of validated technologies for sleep apnea, insomnia, and neurodegenerative disease.
What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?
Nexalin Technology has secured a US patent for its Deep Intracranial Frequency Stimulation (DIFS) platform, protecting its noninvasive, in-home treatment method for insomnia, anxiety, and depression through 2042. The patent reinforces the company’s strategy to expand physician-supervised, drug-free neurostimulation care via its virtual clinic model.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
Melatonin – a go-to sleep aid for kids and adults alike in many households in America – continues to create media buzz, with conflicting messages that leave people uncertain about its safety.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.